Utility of urinary liver-type fatty acid-binding protein as a predictor of renal dysfunction in Japanese patients with HIV receiving tenofovir disoproxil fumarate with low urinary β2 microglobulin levels: a retrospective observational study.
HIV
L-FABP
Renal dysfunction
Tenofovir
Journal
Journal of pharmaceutical health care and sciences
ISSN: 2055-0294
Titre abrégé: J Pharm Health Care Sci
Pays: England
ID NLM: 101672177
Informations de publication
Date de publication:
2019
2019
Historique:
received:
04
01
2019
accepted:
07
05
2019
entrez:
12
6
2019
pubmed:
12
6
2019
medline:
12
6
2019
Statut:
epublish
Résumé
Tenofovir disoproxil fumarate (TDF) is known to reduce estimated glomerular filtration rate (eGFR). It is clinically important to identify patients at high risk for renal dysfunction as early as possible. Among the tubular markers, urinary β2 microglobulin (Uβ2MG) is a well-known biomarker of TDF-related tubulopathy. However, renal dysfunction has often been occurred in patients receiving TDF with low Uβ2MG levels. Recently, urinary liver-type fatty acid-binding protein (UL-FABP) was suggested to be predictor of the progression of renal dysfunction. Thus, we focused on UL-FABP in patients receiving TDF with low Uβ2MG levels. A retrospective, observational, single-center study, between January 2013 and December 2016, was conducted. Two renal end points (> 25% decrement in eGFR and > 20 mL/min/1.73 m A total of 24 Japanese outpatients with human immunodeficiency virus receiving TDF were enrolled. The outcome each occurred in two patients during the follow-up period. UL-FABP levels ≥4.0 μg/g creatinine was significantly associated with > 25% decrement and > 20 mL/min/1.73 m Based on our preliminary analysis, UL-FABP levels ≥4.0 μg/g creatinine predict renal dysfunction in patients receiving TDF with low Uβ2MG levels.
Sections du résumé
BACKGROUND
BACKGROUND
Tenofovir disoproxil fumarate (TDF) is known to reduce estimated glomerular filtration rate (eGFR). It is clinically important to identify patients at high risk for renal dysfunction as early as possible. Among the tubular markers, urinary β2 microglobulin (Uβ2MG) is a well-known biomarker of TDF-related tubulopathy. However, renal dysfunction has often been occurred in patients receiving TDF with low Uβ2MG levels. Recently, urinary liver-type fatty acid-binding protein (UL-FABP) was suggested to be predictor of the progression of renal dysfunction. Thus, we focused on UL-FABP in patients receiving TDF with low Uβ2MG levels.
METHODS
METHODS
A retrospective, observational, single-center study, between January 2013 and December 2016, was conducted. Two renal end points (> 25% decrement in eGFR and > 20 mL/min/1.73 m
RESULTS
RESULTS
A total of 24 Japanese outpatients with human immunodeficiency virus receiving TDF were enrolled. The outcome each occurred in two patients during the follow-up period. UL-FABP levels ≥4.0 μg/g creatinine was significantly associated with > 25% decrement and > 20 mL/min/1.73 m
CONCLUSION
CONCLUSIONS
Based on our preliminary analysis, UL-FABP levels ≥4.0 μg/g creatinine predict renal dysfunction in patients receiving TDF with low Uβ2MG levels.
Identifiants
pubmed: 31183158
doi: 10.1186/s40780-019-0140-8
pii: 140
pmc: PMC6551878
doi:
Types de publication
Journal Article
Langues
eng
Pagination
12Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
Lab Invest. 2009 May;89(5):513-9
pubmed: 19274046
Diabetes Care. 2009 Sep;32(9):1684-8
pubmed: 19502542
Clin Infect Dis. 2010 Sep 1;51(5):496-505
pubmed: 20673002
Curr Hypertens Rep. 2010 Oct;12(5):364-8
pubmed: 20686930
Diabetes Care. 2011 Mar;34(3):691-6
pubmed: 21273494
J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):388-95
pubmed: 23254151
Lancet. 2013 Mar 2;381(9868):735-43
pubmed: 23306000
Nihon Jinzo Gakkai Shi. 2012;54(8):1034-191
pubmed: 23387281
Curr Diab Rep. 2014 Aug;14(8):513
pubmed: 24919751
Clin Exp Nephrol. 2016 Apr;20(2):195-203
pubmed: 26189083
Indian J Nephrol. 2015 Sep-Oct;25(5):269-73
pubmed: 26628791
AIDS. 2016 Jun 19;30(10):1563-71
pubmed: 26919734
Infect Dis (Lond). 2018 Jan;50(1):77-79
pubmed: 28838281
J Infect Chemother. 2018 Mar;24(3):199-205
pubmed: 29150412
Int J STD AIDS. 2018 Dec;29(14):1424-1431
pubmed: 30114996
Annu Rev Nutr. 1987;7:337-59
pubmed: 3300738